Most people who land on this page are looking at one of two scenarios: an ultrasound found a pelvic mass and CA-125 was drawn alongside it, or a "wellness panel" came back with a flagged value and the word "ovarian" lit up every search bar in the house. Both are scary. They are also very different situations.
Here is the part that gets buried: CA-125 is not a screening test for ovarian cancer. The two big randomized trials, UKCTOCS and PLCO, screened hundreds of thousands of women between them and found no mortality benefit, plus a real harm signal from unnecessary surgeries. The USPSTF recommends against ovarian cancer screening for that reason. So if your CA-125 was ordered as part of a routine checkup with no symptoms and no mass, the result on the page is, almost by design, going to be confusing rather than clarifying.
Where the test does pull its weight: characterizing a pelvic mass that is already on imaging (especially in a postmenopausal woman, where the ROMA and RMI scores live), tracking response to treatment in known epithelial ovarian cancer, and watching for recurrence after treatment. Outside those settings, the right question to ask the ordering clinician is, "What decision will this number actually inform?"
What CA-125 actually is
CA-125 (also known as MUC16) is a large glycoprotein expressed on cells that line the abdomen, chest, pericardium, and the female reproductive tract. Anything that irritates, inflames, or invades those surfaces can spill CA-125 into the blood. Cancer is one of those things. So is endometriosis, fibroids, a recent C-section, fluid on the lung, or pregnancy.
About 80 percent of epithelial ovarian cancers (especially serous) secrete CA-125. So do endometrial, fallopian tube, and primary peritoneal cancers. Mucinous ovarian cancers raise it less reliably. Non-epithelial ovarian cancers (germ cell, sex cord-stromal) typically do not raise it at all. Read that as: a "normal" CA-125 in a woman with a concerning ovarian mass does not rule cancer out.
Practically, the protein is a marker of "something is going on near the peritoneum or pelvis," not a marker of cancer specifically. The job of the rest of the workup is to figure out what that something is.
CA-125 cutoffs
| Grupo demográfico | Bajo | Alto | Unidad |
|---|---|---|---|
| Adult (general) | 0 | 35 | U/mL |
| Common in benign disease (endometriosis, fibroids) | 35 | 200 | U/mL |
| High suspicion with pelvic mass | 200 | 10000 | U/mL |
| Doubling from treated nadir (recurrence) | 0 | 0 | GCIG criterion |
The standard cutoff is below 35 U/mL, but a single number lives or dies on context:
- Below 35 U/mL: the "normal" range. Does not rule out ovarian cancer. About half of stage I disease is below 35.
- 35 to 200 U/mL: common in benign conditions like endometriosis, fibroids, pregnancy, PID, and recent abdominal surgery. Cancer is on the differential, but it is not the most likely cause.
- Above 200 U/mL in a postmenopausal woman with a pelvic mass: this is where CA-125 earns its keep. Combined with imaging and HE4 in the ROMA score, it meaningfully raises malignancy probability and changes referral.
- Trending upward during or after ovarian cancer treatment: the most clinically useful pattern in the entire test. A doubling from a treated nadir is a recurrence signal even when imaging still looks clean.
Premenopausal women have higher and more variable CA-125 baselines than postmenopausal women, mostly from cyclic ovarian and endometrial activity. The same value carries different weight before and after menopause.
Why CA-125 goes up, and why most of the time it is not cancer
The list of benign causes is long, and many overlap with the women in whom CA-125 sometimes gets ordered "just to be sure":
- Endometriosis. One of the leading causes of mildly to moderately elevated CA-125 in premenopausal women. Values of 50 to 200 are routine.
- Uterine fibroids.
- Adenomyosis.
- Menstruation. CA-125 typically peaks during menses. If you can, draw the test in the follicular phase.
- Pelvic inflammatory disease.
- Pregnancy, especially the first trimester.
- Recent abdominal or pelvic surgery.
- Cirrhosis with ascites, heart failure with effusions, peritonitis, pancreatitis. Anything that irritates the peritoneum.
- Tuberculosis, especially abdominal or pleural.
- Other cancers. Endometrial, fallopian tube, primary peritoneal, breast, lung, pancreatic, and colon cancers can all elevate CA-125.
How an elevated CA-125 should actually be worked up:
- Is there a pelvic mass on transvaginal ultrasound? Without one, CA-125 alone rarely changes management.
- If there is a mass, combine CA-125 with HE4 and menopausal status to get a ROMA (Risk of Ovarian Malignancy Algorithm) or RMI (Risk of Malignancy Index) score. These are what actually decide whether the referral is to gynecologic oncology or routine gynecology.
- If known ovarian cancer is being monitored, follow the trajectory rather than any single value. A doubling from nadir matters even within the "normal" range.
Low CA-125
A low CA-125 is reassuring in two specific contexts: it tilts an ovarian mass toward benign (especially in a postmenopausal woman), and in a treated ovarian cancer patient it is consistent with remission. There is no clinically meaningful "too low" value.
What a low CA-125 cannot do is rule out ovarian cancer at the screening stage. About half of women with stage I ovarian cancer have CA-125 below 35. That insensitivity at exactly the stage where screening would have to work is the central reason CA-125 fails as a population screening test.
The trend is the test
Where CA-125 quietly excels is monitoring known disease. After surgery and chemotherapy, CA-125 ideally falls into the normal range. That nadir becomes the patient's personal baseline.
Two patterns matter:
- Doubling from nadir on two consecutive measurements. Meets GCIG criteria for biochemical recurrence, even when imaging is still normal. Often precedes radiologic recurrence by 3 to 6 months.
- A drop of more than 50 percent from baseline during chemotherapy. A recognized response indicator.
Whether earlier intervention triggered by a rising CA-125 in asymptomatic patients improves survival is debated. The MRC OV05 trial suggested no overall survival benefit from acting on CA-125 rises before clinical recurrence. Many oncologists therefore use CA-125 trends to guide surveillance frequency and patient discussions rather than to immediately retreat.
For benign elevations like endometriosis or fibroids, the trend is also informative. Stable values over years in someone with known endometriosis are reassuring. A sudden new rise warrants imaging.
Rastrea este biomarcador a lo largo del tiempo en AskAnything.health — sube tus resultados de laboratorio y ve las tendencias de un vistazo.
When CA-125 actually warrants action
- Elevated CA-125 with a pelvic mass on imaging in a postmenopausal woman. Calculate ROMA or RMI and refer to gynecologic oncology if elevated.
- Rising trend during ovarian cancer surveillance, especially doubling from nadir on two consecutive measurements.
- Markedly elevated CA-125 (above 200 U/mL) without an obvious benign explanation, even without a clearly defined mass. Worth imaging and further workup.
- Strong family history (BRCA1/2, Lynch syndrome) with new pelvic symptoms. Lower threshold to investigate, even with mildly elevated CA-125.
What does not warrant action: an isolated mildly elevated CA-125 in a premenopausal woman with no mass, no symptoms, and a plausible benign cause (menses, endometriosis, fibroids). Repeat in a different cycle phase if needed, but resist the imaging spiral that often follows a "borderline" CA-125 ordered without a clear question behind it.
Esta información es solo con fines educativos y no sustituye el consejo médico profesional. Siempre consulta a tu proveedor de salud sobre tus resultados de laboratorio.
Tests that complete the picture
- HE4 (human epididymis protein 4). Paired with CA-125 in the ROMA score. Less reactive to benign gynecologic conditions, so it improves specificity.
- Transvaginal ultrasound. The primary imaging test for any suspected pelvic mass. CA-125 without imaging rarely changes management.
- CEA. Helps distinguish primary ovarian cancer (typically CEA-low, CA-125-high) from metastatic GI cancer (typically CEA-high).
- CA 19-9. Sometimes elevated in mucinous ovarian cancers when CA-125 is not.
- AFP, beta-hCG, LDH. For non-epithelial (germ cell) ovarian tumors, which CA-125 misses.
- BRCA1/2 and Lynch syndrome genetic testing. Far more impactful for ovarian cancer risk assessment than CA-125 in average-risk women.